Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases

Inflammatory Bowel Diseases(2020)10.1093/ibd/izaa327Source: DataRank Database

Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases is a research paper published in Inflammatory Bowel Diseases (2020). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 3.52)OA: bronzeTopics (35)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Herbert C. Heien,Lindsey R. Sangaralingham ORCID,Nilay D. Shah ORCID,Jennifer C. Lai ORCID,William J. Sandborn ORCID

Live enrichment

PubMed:33325507 OpenAlex:https://openalex.org/W3113337130

NIDDK

Grant: K23DK117058

NIH

Grant: R01AG059183

NIH

Grant: P30 DK120515

NIH

Grant: P30 AG059299

NIDDK NIH HHS

Grant: R03 DK129631

FWCI

3.52

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

journalhttps://academic.oup.com/ibdjournal/article-pdf/27/10/1626/40715643/izaa327.pdf

publisherhttps://academic.oup.com/ibdjournal/article-pdf/27/10/1626/40715643/izaa327.pdf

publisherhttps://academic.oup.com/ibdjournal/article-pdf/27/10/1626/45955421/izaa327.pdf

journalhttps://doi.org/10.1093/ibd/izaa327

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33325507

Fields of Study

Inflammatory Bowel DiseaseChronic Disease Management StrategiesRheumatoid Arthritis Research and TherapiesBiological ProductsFrailtyHumansInflammatory Bowel DiseasesMiddle AgedRetrospective StudiesTumor Necrosis Factor-alpha

MeSH Terms

FrailtyBiological ProductsHumansMiddle AgedRetrospective StudiesTumor Necrosis Factor-alphaInflammatory Bowel Diseases

Keywords

MedicineVedolizumabInternal medicineHazard ratioInflammatory bowel diseaseComorbidityRetrospective cohort studyProportional hazards modelCohortCohort studyCrohn's diseaseDiseaseConfidence intervalcolitisdebilityenteritisimmune suppressioninfestation

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis

10.6084/m9.figshare.22609091.v1figshare

Additional file 1 of Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis

10.6084/m9.figshare.22609091figshare